Rio.ai has raised ₹43.08 crore in a pre-Series A funding round, continuing its work on its medicines-focused, AI-powered quick-commerce platform. The investment was led by Version One Ventures. The round saw active participation from existing investors Xeed Ventures, Good Capital, and Amplify Partner. The investment is a substantial capital injection for the growing healthcare tech company, bolstering its market standing and technological backbone.

Valuation breakdown and ownership structure

As per the regulatory documents made available to Entrackr, the board of Rio.ai authorized the allotment of ₹7,130 compulsorily convertible (CCP) preference shares at a price of ₹60,415 per Share for the fund size of ₹43.08 crore. The capital contribution analysis indicates that Version One Ventures led the funding round with a significant investment of ₹21.30 crore. 

Existing investor Xeed Ventures invested ₹11.84 crore in the startup, while the Good Capital Fund II invested ₹9.47 crore in the startup. Amplify IV PCC participated in the round by investing ₹47 lakh. According to Entrackr, in this recent equity sale, Rio.ai’s post-money value is estimated at roughly ₹170 crore.

Since completion of this most recent share allotment, there have been significant changes to the ownership dynamics of Rio.ai’s main institutional shareholders and founding partners. Institutional investor Xeed Ventures has increased its stake to become the biggest single shareholder with 21.11%. 

Version One Ventures is the lead investor, holding a 12.86% equity stake in the startup, while Good Capital has a control stake of 17.07%. The founding team, led by co-founders, Ankur Agrawal and Amit Ahuja, continues to have a meaningful stake in rival, each with 17.50% shareholding in Rio.ai.

Capital utilization and core platform offerings

The increased capital of ₹43.08 crore pledged will be invested in a range of potential strategies for the operations and growth of Rio.ai. The company is expected to use the new disposable cash flow for general operating and daily working capital, as detailed in the source documentation. 

The capital will also contribute to operational expenditure and be channeled into capital expenditure projects, building up the firm’s own financial capital base and overall business growth across target markets.

Rio.ai was founded by Ankur Agrawal and Amit Ahuja with the aim of creating a dedicated quick-commerce ecosystem for healthcare accessibility. This company is responsible for the Rio Health platform that incorporates artificial intelligence into the healthcare delivery chain. 

Consumers can place orders for critical medicines and other healthcare products conveniently via WhatsApp on the platform. The service is designed to operate at extremely high speeds, ensuring that healthcare products reach users at a turnaround time of as little as 15-30 minutes.

This pre-Series A equity raise comes after a slew of market reports about the financial activities of the healthtech company. Before this investment disclosure, a report by Moneycontrol had revealed that Rio.ai was noted to be in discussions for investment of around $5 million. 

The initial negotiations reportedly included leading investors such as Binny Bansal, investment funds from Canada, and other stakeholders, with the structured deal at this stage handled by investment firm Version One Ventures.

Conclusion

The raise of ₹43.08 crore in pre-Series A funding reflects increasing investor confidence in Rio.ai and its niche solution to rapid healthcare delivery. The investment will provide the financial support needed to accelerate its expansion plans and enhance the efficiency of its AI-powered quick-commerce solutions, with existing venture partners providing solid backing for the venture, led by Version One Ventures. However, with its growing presence and technological infrastructure, the company remains a significant player in the dynamic healthtech and delivery marketplace as it continues to expand its operations.